LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, has completed its randomized, 12-week human clinical trial evaluating the efficacy of its innovative GLP-1 system for weight management. The study was conducted to explore the system’s potential to activate GLP-1 in users and support their health goals. * †
The clinical trial, which began in mid-June 2024, involved 60 participants and was designed to assess the impact the innovative two-product system has on weight management, food cravings, and overall well-being, among other factors. * †
Participants were divided into three groups to evaluate the system’s effects under different conditions, comparing the product system alone, the product system combined with diet and exercise guidance, and a control group, over the course of the three-month period.
“We are thrilled to have completed this key phase of our research and for the results we are seeing with these products,”
said Lisa Barnes, Vice President of Research, Development & Regulatory at LifeVantage.
“The data from this human clinical shows a remarkable ability of our unique two-product system to address weight management challenges through the natural activation of the health-supporting hormone, GLP-1. We remain confident that